Anti-amyloid trial (Clarity-AD lecanemab)

Layer 3 — Biologyin the Neurodegenerative Disease subtree

van Dyck 2023 Clarity-AD: lecanemab (Eisai/Biogen) reduced clinical-decline 27% vs placebo in early AD over 18 months; ARIA-edema/hemorrhage in 12-17%; FDA-approved 2023; next-gen donanemab confirmed 2024.

Related concepts

Expectation E[X]

Explore Anti-amyloid trial (Clarity-AD lecanemab) on the interactive knowledge graph →